Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial.
Klaus Stahl, Philipp Wand, Benjamin Seeliger...
https://pubmed.ncbi.nlm.nih.gov/35551628/Actively Recruiting
Led by Hannover Medical School · Updated on 2025-03-13
274
Participants Needed
25
Research Sites
8 weeks
Total Duration
Septic shock is a life-threatening condition caused by a harmful response to infection that leads to organ failure and high risk of death. This trial is designed to evaluate whether adding therapeutic plasma exchange TPE early in treatment can reduce organ damage and improve outcomes in patients with early septic shock. The study addresses a critical need for more specific treatments beyond current supportive care. Participants will be randomly assigned to receive either one or two sessions of TPE using donor fresh frozen plasma within the first day after randomization or standard care without TPE. The first TPE session occurs within 6 hours and lasts about 2 to 3 hours, with a second session possible if high doses of vasopressors are still needed. Plasma is replaced at a fixed volume ratio to the patients plasma. Anticoagulants like heparin or citrate may be used during TPE. During the study, researchers will monitor participants for 28 days to assess survival, organ function, and need for organ support. They will collect detailed data on organ failure scores, heart and lung function, blood tests, infections, and length of hospital stay. Safety and treatment effects will be closely followed up to 90 days after randomization. The overall study duration varies per patient based on recovery and hospital discharge.
CONDITIONS
Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock
S
Sascha David, Prof. Dr.
K
Klaus Stahl, PD Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Hannover Medical School
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Screening and enrollment visit
Duration - Up to 2 days
Participants receive Therapeutic Plasma Exchange (TPE) treatment to help reduce organ dysfunction caused by septic shock. The first TPE is performed within 6 hours after randomization, lasting approximately 120 to 180 minutes. A second TPE may be performed if participants remain vasopressor dependent 24 hours after the first treatment.
1 to 2 treatment sessions depending on clinical response
Duration - Up to 90 days after randomization
Participants are monitored for outcomes including organ function and survival after treatment.
Daily assessments for 7 days, then regular monitoring until day 90
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Klaus Stahl, Philipp Wand, Benjamin Seeliger...
https://pubmed.ncbi.nlm.nih.gov/35551628/Sascha David, Christian Bode, Christian Putensen...
https://pubmed.ncbi.nlm.nih.gov/33471132/Klaus Stahl, Julius J Schmidt, Benjamin Seeliger...
https://pubmed.ncbi.nlm.nih.gov/32122366/Hannah Knaup, Klaus Stahl, Bernhard M W Schmidt...
https://pubmed.ncbi.nlm.nih.gov/30373638/Klaus Stahl, Rolf Bikker, Benjamin Seeliger...
https://pubmed.ncbi.nlm.nih.gov/33063613/Klaus Stahl, Uta Carola Hillebrand, Yulia Kiyan...
https://pubmed.ncbi.nlm.nih.gov/34817751/Sascha David, Christian Bode, Klaus Stahl...
https://pubmed.ncbi.nlm.nih.gov/37061693/Hannover Medical School
Lead Sponsor